Lori Elizabeth Mochan

Founded in 2019, Tungsten Bidco Ltd. is a British company that functions as an investment holding company. Part of Biogen, Inc., the company is based in Maidenhead, UK.

NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom.

Part of Amicus Therapeutics, Inc., Amicus Therapeutics UK Ltd. is a company that focuses on delivering high-quality therapies for persons living with rare and orphan diseases. The company is based in Gerrards Cross, UK. The employees of Amicus crafted a belief statement that encompasses their core values and reminds them of the reason they do what they do every day. The statement outlines the fundamental beliefs that are crucial to understanding the passion and commitment behind Amicus. The British company believes in the fight to remain at the forefront of therapies for rare and orphan diseases, supporting the disease communities and their families, and fostering teamwork and respect for each individual's contribution.

Part of Amicus Therapeutics, Inc., Amicus Therapeutics UK Ltd. is a company that focuses on delivering high-quality therapies for persons living with rare and orphan diseases. The company is based in Gerrards Cross, UK. The employees of Amicus crafted a belief statement that encompasses their core values and reminds them of the reason they do what they do every day. The statement outlines the fundamental beliefs that are crucial to understanding the passion and commitment behind Amicus. The British company believes in the fight to remain at the forefront of therapies for rare and orphan diseases, supporting the disease communities and their families, and fostering teamwork and respect for each individual's contribution.

NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom.

Part of Amicus Therapeutics, Inc., Amicus Therapeutics UK Ltd. is a company that focuses on delivering high-quality therapies for persons living with rare and orphan diseases. The company is based in Gerrards Cross, UK. The employees of Amicus crafted a belief statement that encompasses their core values and reminds them of the reason they do what they do every day. The statement outlines the fundamental beliefs that are crucial to understanding the passion and commitment behind Amicus. The British company believes in the fight to remain at the forefront of therapies for rare and orphan diseases, supporting the disease communities and their families, and fostering teamwork and respect for each individual's contribution.